Case Studies


Some of the clients we have completed working with provide real-life examples of what we do in practice.

Case Studies

GXPi

GXPi is a provider of specialist consulting services to help Life Science organisations achieve their compliance goals.

We advised on strategy, then moved to the equity stage, which then progressed to exit and acquisition by a Scandinavian consultancy.

Excelsyn

We created Excelsyn, a business offering process research, development and scale up of drug substance manufacture to the global pharmaceutical and biotechnology industry, around the acquisition of a Great Lakes Fine Chemicals site in June 2004.  We grew the business rapidly, received backing from 2 VCs and then sold the company to AMRI.

Please click here to download a presentation of our work with Excelsyn.

Epigem

Epigem is a polymer micro engineering company specialising in the life sciences development and manufacture of microfluidic devices.

We worked on a retainer base, provided an Interim CEO, developed a new strategy and 5-year business plan and instigated monthly board meetings and management acounts and dashboards and designed a new organisation structure focused on generating cash.

In 2013, they secured over £2million of funding for a number of high tech projects to accelerate the company’s growth in healthcare markets.

BioCatalysts

Biocatalysts is a global biotechnology company producing speciality enzymes at commercial scales.

An already profitable business, we helped them look at how to grow the business and improve Executive Management and accounting, and restructure the shareholder base.

Subsequently, the company has expanded manufacturing capacity and continues to grow, with plans as far as 2020 and beyond.

Chemoxy International

Chemoxy is one of the largest independent contract chemical manufacturers in Europe.

Working with the Board, we evaluated external market opportunities and internal capabilities and helped prepare a measured and credible growth plan and provided a platform for investment by the Business Growth Fund despite difficult market conditions in their core Oil & Gas sector.

Sanofi

Sanofi is the world's 5th largest drug company by prescription sales.

We were engaged to provide a science-based legacy of employment for the Fawdon site they were vacating. We created a masterplan to repurpose the site as a life science business park to accommodate a portfolio of start-up and early growth businesses.

We secured interest from over a dozen such businesses and then moved to help market the site to potential acquisitors, culminating in a successful transaction.